Stem Cell Therapy Shows Promise for Alzheimer's Disease in Combination Trial
核心洞察
A new clinical trial at the University of Miami is evaluating whether a single infusion of mesenchymal stem cells (搜索) combined with anti-amyloid therapy can stabilize cognitive decline in early Alzheimer's disease (搜索).
The study builds on a prior Phase I trial of Lomecel-B that showed no serious adverse events and suggested cognitive stabilization at lower doses with favorable biomarker changes.
The dual-target approach addresses both amyloid accumulation and neuroinflammation, leveraging the immunomodulatory and regenerative properties of mesenchymal stem cells (搜索).
A clinical trial at the University of Miami Miller School of Medicine is investigating whether a single infusion of mesenchymal stem cells (搜索), administered alongside standard anti-amyloid therapy, can stabilize cognitive decline in individuals with early Alzheimer's disease (搜索) and mild cognitive impairment. The study represents a novel dual-target approach that addresses both the amyloid pathology and the neuroinflammation driving disease progression.
A Dual-Target Strategy for Early Alzheimer's
The trial focuses on early-stage Alzheimer's patients who are currently receiving anti-amyloid monoclonal antibodies, specifically Leqembi (lecanemab) or Kisunla (donanemab). While these treatments help eliminate amyloid plaques and slow disease progression, they do not halt it entirely. "We have data that shows us how people do on these drugs," said Dr. Bernard Baumel, a principal investigator on the study. "It's like a ski slope. Over time, the slope changes. It's still a ski slope, but it's not as steep a ski slope, if you take the medications. You end up going down the hill slower."
The study adds a one-time intravenous infusion of human mesenchymal stem cells (搜索) (hMSCs) to evaluate whether this combination can further improve outcomes. The stem cell therapy is administered after six months of antibody treatment, a deliberate delay designed to minimize confounding safety signals from overlapping treatments.
The Role of Neuroinflammation
The study is grounded in the growing recognition that Alzheimer's disease (搜索) involves more than amyloid accumulation alone. Neuroinflammation is increasingly understood as a key driver of disease progression. "There's a lot of brain inflammation in people with Alzheimer's disease," Baumel explained. "We know removing the amyloid reduces inflammation, and that may be why it slows the progression."
Mesenchymal stem cells (搜索) may offer a complementary approach due to their immunomodulatory and regenerative properties. These cells can migrate to sites of injury, release anti-inflammatory molecules, and promote tissue repair. "Stem cells are also very potent anti-inflammatories," Baumel noted. "So that may add to the anti-inflammatory effect of removing the amyloid. Our theory is that adding another anti-inflammatory medication, a potent one like stem cells, can really be helpful."
Building on Phase I Evidence
The current trial builds on a previously published Phase I study of Lomecel-B, a mesenchymal stem cell-based therapy, in patients with mild Alzheimer's disease (搜索). That earlier trial employed a randomized, double-blind design in which patients received a single intravenous infusion of either stem cells or placebo. The primary endpoint was safety, and it was successfully met, with no treatment-related serious adverse events reported.
Exploratory findings from the Phase I study suggested potential clinical benefit. Patients receiving lower-dose stem cell infusions showed improved or stabilized cognitive performance compared to placebo, along with favorable changes in biomarkers related to inflammation and vascular function. Fluid-based and imaging outcomes also indicated that stem cell therapy may influence multiple aspects of Alzheimer's pathology, including neuroinflammation and neurovascular health.
Trial Eligibility and Design
Eligible participants must be between 55 and 90 years old, have a diagnosis of mild cognitive impairment due to Alzheimer's disease (搜索) or mild Alzheimer's disease, and demonstrate a Mini-Mental State Examination (MMSE) score between 20 and 26. Participants must also retain sufficient cognitive capacity to provide consent independently and have a designated study partner to help assess daily functioning. Participants will be monitored longitudinally following the stem cell infusion, with outcomes focused on whether cognitive decline stabilizes or improves.
Market Context
According to Precedence Research, the global stem cell therapy market for neurological disorders was valued at USD 2.38 billion in 2025 and is projected to grow from USD 2.81 billion in 2026 to approximately USD 12.67 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.90% from 2026 to 2035. This growth is driven by the rising prevalence of neurological disorders and the increasing pace of stem cell innovation and clinical trials.